Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and ImmunotherapyJoseph Tintelnot, Mascha Binder, Susanna Hegewisch-Becker et al.|Cancer Immunology Research|2024Cited by 6
Supplementary Figure 1 from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and ImmunotherapyJoseph Tintelnot, Mascha Binder, Lisa Paschold et al.|Unknown|2025Cited by 0
Supplementary Figure 3 from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and ImmunotherapyJoseph Tintelnot, Mascha Binder, Lisa Paschold et al.|Unknown|2025Cited by 0
Supplementary Figure 2 from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and ImmunotherapyJoseph Tintelnot, Mascha Binder, Lisa Paschold et al.|Unknown|2025Cited by 0
Data from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and ImmunotherapyJoseph Tintelnot, Mascha Binder, Lisa Paschold et al.|Unknown|2025Cited by 0